Nvidia Invests in Generate Biomedicines to Enhance AI Drug Discovery
Nvidia's venture arm, NVentures, has disclosed ownership of 833,325 shares in Generate Biomedicines, valued at around $10.4 million, according to Nvidia's latest 13F filing from May 2026. Generate, listed on Nasdaq under the ticker GENB, is focused on creating an AI-powered platform that automates the generation and optimization of therapeutic proteins, aiming to significantly shorten the drug discovery timeline.
The company employs generative AI models to design proteins and drug candidates from the ground up. Currently, Generate is advancing beyond theoretical applications, with a Phase 3 clinical trial for severe asthma underway, which is the final testing phase before seeking regulatory approval. Additionally, it has multiple oncology candidates that have received FDA Fast Track designation, a status granted to treatments addressing serious conditions with unmet medical needs.
For Your Trading Desk
Sponsor Spike Success.
Since its inception, Generate has raised approximately $700 million in funding. NVentures first participated during Generate's $273 million Series C funding round, which concluded in September 2023 and included contributions from Amgen, a leading biotech firm. Generate went public with a Nasdaq IPO in February 2026.
While a $10.4 million stake may seem minor for a company of Nvidia's scale, this investment is part of Nvidia's broader strategy to cultivate a customer ecosystem that will rely on its chips for years to come. The drug discovery process, which includes simulating protein folding and predicting molecular interactions with human biology, requires the parallel processing capabilities that Nvidia's hardware is designed to provide.
However, the investment carries risks. As a clinical-stage company, Generate has yet to generate significant revenue from approved products. Phase 3 trials can fail, and Fast Track designation does not guarantee approval. The $700 million raised will need to sustain the company through potentially lengthy clinical processes.
For investors in Nvidia or related AI infrastructure, Generate's progress in clinical trials is an important metric to monitor. A successful Phase 3 outcome for the severe asthma program could not only impact GENB's stock but also reinforce the notion that AI-driven computing is becoming essential across various industries, supporting Nvidia's growth narrative.




